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Melanoma,	Viagra	and	PDE5	inhibitors:	proliferation	and	metastasis	
	
By	
	
Miles	D	Houslay*#		
	
	
Abstract	
	 Inhibitors	of	PDE5	cGMP	degrading	phosphodiesterases	have	realised	blockbuster	status	
for	treating	penile	erectile	dysfunction.		Indeed,	their	re-purposing	is	currently	being	proposed	to	
treat	certain	solid	tumours	and	various	other	diseases.		In	a	cruel	irony,	however,	it	appears	from	
recent	clinical	studies	that	PDE5	inhibitors	may	actually	increase	malignant	melanoma	risk	by	
negating	newly	identified	brakes	on	proliferation	and	metastasis	provided	by	PDE5A.		
	
Article	Body	
Things	were	simpler	when	cAMP	and	cGMP	were	the	only	second	messenger	signalling	
systems	known.	Now	we	are	faced	with	a	myriad	of	signalling	systems	such	that	trying	to	
comprehend	their	integrated	functioning	is	challenging	both	technically	and	intellectually.	This	is	
further	complicated	as	their	functioning	is	invariably	tailored	in	a	cell-type	specific	fashion	to	
confer	distinct	modes	of	compartmentalization	and	regulation	[1,	2].		
Over	the	past	few	decades	there	has	been	an	overwhelming	focus	of	academic	research	on	
the	more	recently	discovered	‘trendy’	signalling	pathways,	while	the	cAMP	and	cGMP	pathways	
have	had	a	more	niche	profile.	In	contrast,	the	pharmaceutical	industry	has	been	profitably	mining	
the	cyclic	nucleotide	area,	generating	a	variety	of	blockbuster	therapeutics.	However,	elucidation	
of	the	roles	of	cAMP	and	cGMP	in	the	key	areas	of	cell	growth	and	proliferation	has	so	far	proved	
elusive,	not	least	because	they	can	elicit	very	different,	and	even	diametrically	opposed,	actions	in	
different	cell	types.	There	is	a	growing	realisation	of	the	importance	of	the	need	to	understand	
this	in	order	to	aid	in	treating	and	diagnosing	certain	cancers.	This	will	require	analysis	of	cells	in	
health	and	in	disease,	where	effective	therapy	will	require	a	personalized	medicine	approach.	
It’s	becoming	increasingly	apparent	that	the	cell	type-specific	behaviour	of	both	cAMP	and	
cGMP	signalling	is	critically	shaped	by	action	of	a	super-family	of	cyclic	nucleotide	degrading	
phosphodiesterases	(PDEs)	differing	in	substrate	specificity,	mode	of	regulation	and	intracellular	
localization	[1].		Of	these,	the	cGMP	specific	PDE5A	has	attracted	much	attention	because	specific	
inhibitors,	Viagra®	(sildenafil),	Zydena®	(udenafil),	Cialis®	(tadalafil),	and	Levitra®	(vardenafil),	are	
effective	in	treating	penile	erectile	dysfunction	(PED).		However,	a	few	years	ago	it	was	suggested	
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that	the	therapeutic	use	of	PDE5	selective	inhibitors	may	negatively	impact	on	malignant	
melanoma,	an	extremely	aggressive	cancer	[3].	Indeed,	this	prediction	appears	to	have	credence	
as	two	recent	clinical	studies	indicate	that	PDE5	inhibitor	usage	causes	a	modest	increase	in	the	
risk	of	melanoma	[4,	5].		
What	links	PDE5	to	melanoma?	The	first	mechanistic	insight	came	from	observations	[3]	
that	PDE5A	was	down-regulated	in	a	large	number	of	melanoma	lines	expressing	oncogenic		
Val600Glu-BRAF	where	cells	adopt	a	de-differentiated,	metastatic	phenotype.	The	underpinning	
mechanism	involved	Val600Glu-BRAF	driven	Erk	activation	causing	up-regulation	of	BRN-2,	which	
inhibits	PDE5A	transcription	and	so	attenuates	cGMP	degradation.		Increased	cGMP,	caused	by	
PDE5A	loss,	elicits	phenotypic	change	via	Ca2+	elevation	and	MLCK	phosphorylation.			Here,	PDE5	
inhibitors	have	little	impact	on	the	majority	of	Val600Glu-BRAF-melanomas	because	PDE5	has	
undergone	severe	down-regulation,	but	does	impact	to	promote	metastasis	on	the	small	
population	where	significant	PDE5	remains.			
The	second	key	insight	has	just	been	uncovered	[6].	This	involves	a	novel	cGMP	signalling	
pathway	in	melanoma	cells	lacking	an	activating	BRAF	mutation.		Here,	a	large	increase	in	cGMP	is	
elicited	through	activation	of	membrane-bound	guanylyl	cyclase	B	(GCB)	by	pro-melanomagenic	C-
type	natriuretic	peptide	(CNP),	which	is	released	by	the	tumour	vasculature,	particularly	under	
inflammatory	conditions.	Through	an	unknown	means,	activated	cGMP	kinase-Iα	(PKG-Iα)	
stimulates	Erk	signalling,	promoting	melanocyte	proliferation	rather	than	promoting	a	metastatic	
phenotype.		In	these	melanomas,	inhibiting	cGMP	degradation	through	PDE5	inhibition	enhances	
the	growth	promoting	effect	of	CNP	and	thus	tumour	size.		
In	both	these	instances	PDE5	provides	a	brake	that,	depending	on	the	melanoma	type,	
constrains	either	proliferation	or	de-differentiation	to	a	metastatic	phenotype.	PDE5	inhibitors	can	
release	this	brake.	
It	may	be	that	cGMP	elevation	in	a	sub-compartment	controlled	by	PDE5A	leads	to	a	
metastatic	signal,	while	cGMP	elevation	due	to	GCB	activation	in	a	distinct	sub-compartment	leads	
to	proliferative	signal	that	is	merely	amplified	upon	PDE5A	inhibition.		However,	other	
complicating	factors	probably	come	into	play	here.	Interestingly,	melanomas	contain	
phenotypically	mixed	melanocyte	populations	where	hypoxic	microenvironments	provide	an	
important	driving	factor	in	this	heterogeneity,	influencing	proliferation	and	metastasis	[7].	Indeed,	
hypoxia	potently	reduces	expression	of	microphthalmia-associated	transcription	factor	(MITF),	the	
master	gene	of	melanoma	differentiation,	through	the	Hif1α	induction	of	the	transcriptional	
repressor,	DEC1	[8].	Melanocytes	with	low	MITF	levels	exhibit	a	de-differentiated,	invasive	
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phenotype,	while	those	with	high	MITF	do	not	[7].		Intriguingly,	it	is	possible	to	relate	this	back	to	
these	recent	key	discoveries	concerning	PDE5A.	This	is	because	high	MITF	increases	levels	of	the	
pigment-cell-enriched	microRNA,	miR-211,	which	originates	from	the	TRPM1	(melastatin)	gene.	
This	represses	BRN-2	[9],	the	transcriptional	repressor	of	PDE5A	[3].		Thus	hypoxic	melanoma	
microenvironments	generate	sub-populations	of	melanocytes	with	low	MITF	and	PDE5A	levels.	
The	ensuing	elevated	cGMP	in	the	PDE5A	sub-compartment	consequently	promotes	the	
metastatic	phenotype.	Conversely,	cells	with	high	MITF	will	be	protected	against	de-differentiation,	
retaining	both	a	proliferative	phenotype	and	sensitivity	to	the	growth	promoting	action	of	PDE5	
inhibitors.			
Clearly	it	is	critical	to	appreciate	the	role	of	PDE5A	and	action	of	all	therapeutic	PDE5	
inhibitors	in	melanocytes	expressing	a	range	of	oncogenic	mutations.		Associated	with	this,	there	
is	a	need	to	identify	the	PKG	isoforms	expressed	in	such	cells,	their	compartmentalisation	and	
relationship	to	PDE5A,	as	recent	evidence	indicates	that	while	PKG-Iα	activation	promotes	cell	
growth	PKG-Iβ	inhibits	it	[6].	As	PDE5	is	not	the	only	cGMP	degrading	PDE,	it	is	also	important	to	
determine	which	other	such	PDEs	melanocytes	express	and	if	their	inhibition	exerts	effects	similar	
to	those	of	PDE5	inhibitors	or	whether	they	control	functionally	distinct	pools	of	cGMP.			
As	all	PDE5	selective	inhibitors	have	potential	to	release	a	brake	provided	by	PDE5A	on	
deleterious	proliferation	and	metastasis	in	certain	melanomas,	it	will	be	important	to	consider	
having	prospective	clinical	studies	undertaken	to	assess	the	significance	of	this	potential	issue.		
These	should	have	clearly	defined	inclusion	and	exclusion	criteria	and	set	doses	of	various	PDE5	
inhibitors	in	order	to	determine	whether	any	recommendation	should	be	made	regarding	their	
clinical	use.	PDE5	inhibitors	are	not	used	chronically	in	PED	and	are	usually	cleared	rapidly.		
However,	careful	consideration	of	the	‘melanoma	question’	will	have	to	be	given	regarding	the	
other	therapeutic	indications	that	PDE5	inhibitors	are	either	used	in	now	or	are	being	considered	
as	these	will	involve	chronic	administration	and	high	systemic	[10].			
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Figure.	
	
PDE5	at	the	centre	of	Phenotype	Switching	in	Melanoma.	
	
Panel	(a).	In	melanocytes	lacking	activated	V600E-BRAF	then	CNP	activated	guanylate	cyclase	B	
increases	cGMP,	which	elicits	a	proliferative	(GREEN)	response	through	an	undefined	PKG-Iα	/	Erk	
–	driven	pathway.	A	brake	(RED)	is	imposed	on	this	by	PDE5,	which	can	be	overcome	by	PDE5	
inhibitors.	It	is	proposed	here	that	hypoxia	(GREY	BOX)	may	also	amplify	switching	to	a	
proliferative	phenotype,	in	this	case	by	lowering	MITF	levels	in	a	Hif1a-driven	fashion	in	order	to	
remove	the	inhibitory	effect	of	miR-211	on	BRN2	transcription	and	so	decreasing	PDE5A	
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expression.	(RED	=	brake	supplied	by	PDE5;	GREEN	=	proliferative	phenotype	switching	signals	
provided	by	PDE5	inhibitors	and,	potentially,	hypoxia).	
	
Panel	(b).	In	V600E-BRAF	expressing	melanocytes,	the	brake	(red)	that	PDE5A	exerts	on	cGMP	
driven	metastasis	is	released	when	PDE5	levels	are	diminished	through	activation	of	the	
transcriptional	repressor,	BRN2	via	an	activated	BRAF/Erk	pathway.		Populations	of	V600E-BRAF	
expressing	melanocytes	show	variation	in	the	level	of	PDE5	reduction	and	those	expressing	
residual	PDE5	will	be	susceptible	to	the	action	of	PDE5	inhibitors,	which	will	potentiate	the	
development	of	a	de-differentiated,	metastatic	phenotype.		It	is	proposed	here	that	hypoxia	(GREY	
BOX)	may	also	amplify	switching	to	a	metastatic	phenotype,	in	this	case	by	lowering	MITF	levels	in	
a	Hif1a-driven	fashion	in	order	to	remove	the	inhibitory	effect	of	miR-211	on	BRN2	transcription	
and	so	decreasing	PDE5A	expression.		(RED	=	brake	supplied	by	PDE5;	GREEN	=	metastatic	
phenotype	switching	signals	provided	by	PDE5	inhibitors,	activated	V600E-BRAF	and,	potentially,	
hypoxia).	
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